Tamara P Miller1,2, Brian T Fisher3,4,5,6, Kelly D Getz4,6,7, Leah Sack7, Hanieh Razzaghi7,8, Alix E Seif5,7, Rochelle Bagatell5,7, Peter C Adamson5,7, Richard Aplenc4,5,6,7,8. 1. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia. 2. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 3. Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 4. Center for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 6. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 7. Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 8. Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Adverse events (AEs) on Children's Oncology Group (COG) trials are reported manually by clinical research assistants (CRAs). The Common Terminology Criteria for Adverse Events (CTCAE) was developed to provide standardized definitions for identifying and grading AEs. The CTCAE has expanded significantly over its five versions, but the impact of CTCAE definitional changes has not been examined. PROCEDURE: This study compared AE number and ascertainment among the first four CTCAE versions using a case vignette. Each CTCAE version was used to create a list of AEs and grades by two separate CRAs. RESULTS: The CTCAE expanded from 9 categories and 49 AEs in v1.0 to 26 categories and 790 AEs in v4.0. CRAs independently selected different approaches to AE ascertainment-comprehensive and parsimonious. The number of AEs identified in the parsimonious approach was stable with 10-14 in each CTC version. The comprehensive approach identified 9, 20, 29, and 37 AEs in CTC versions 1.0, 2.0, 3.0, and 4.0, respectively. Only approximately 65% of AEs were conclusively graded in versions 2.0 to 4.0 using the comprehensive approach. CONCLUSIONS: CTCAE has increased in complexity. Although this increased complexity allows for more granular AE reporting, these data demonstrate potential unintended negative consequences of increasing CTC AE complexity, including the risk of varying approaches to AE capture. A comprehensive evaluation of CTC AE definitions and CRA reporting practices across COG institutions and AEs are needed to improve the accuracy and efficiency of AE reporting.
BACKGROUND: Adverse events (AEs) on Children's Oncology Group (COG) trials are reported manually by clinical research assistants (CRAs). The Common Terminology Criteria for Adverse Events (CTCAE) was developed to provide standardized definitions for identifying and grading AEs. The CTCAE has expanded significantly over its five versions, but the impact of CTCAE definitional changes has not been examined. PROCEDURE: This study compared AE number and ascertainment among the first four CTCAE versions using a case vignette. Each CTCAE version was used to create a list of AEs and grades by two separate CRAs. RESULTS: The CTCAE expanded from 9 categories and 49 AEs in v1.0 to 26 categories and 790 AEs in v4.0. CRAs independently selected different approaches to AE ascertainment-comprehensive and parsimonious. The number of AEs identified in the parsimonious approach was stable with 10-14 in each CTC version. The comprehensive approach identified 9, 20, 29, and 37 AEs in CTC versions 1.0, 2.0, 3.0, and 4.0, respectively. Only approximately 65% of AEs were conclusively graded in versions 2.0 to 4.0 using the comprehensive approach. CONCLUSIONS:CTCAE has increased in complexity. Although this increased complexity allows for more granular AE reporting, these data demonstrate potential unintended negative consequences of increasing CTC AE complexity, including the risk of varying approaches to AE capture. A comprehensive evaluation of CTC AE definitions and CRA reporting practices across COG institutions and AEs are needed to improve the accuracy and efficiency of AE reporting.
Authors: Alice P Chen; Ann Setser; Milan J Anadkat; Jonathan Cotliar; Elise A Olsen; Benjamin C Garden; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2012-04-11 Impact factor: 11.527
Authors: R Aplenc; B T Fisher; Y S Huang; Y Li; T A Alonzo; R B Gerbing; M Hall; D Bertoch; R Keren; A E Seif; L Sung; P C Adamson; A Gamis Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Shanthi Sivendran; Asma Latif; Russell B McBride; Kristian D Stensland; Juan Wisnivesky; Lindsay Haines; William K Oh; Matthew D Galsky Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Tamara P Miller; Kelly D Getz; Yimei Li; Biniyam G Demissei; Peter C Adamson; Todd A Alonzo; Evanette Burrows; Lusha Cao; Sharon M Castellino; Marla H Daves; Brian T Fisher; Robert Gerbing; Robert W Grundmeier; Edward M Krause; Judy Lee; Philip J Lupo; Karen R Rabin; Mark Ramos; Michael E Scheurer; Jennifer J Wilkes; Lena E Winestone; Douglas S Hawkins; M Monica Gramatges; Richard Aplenc Journal: Lancet Haematol Date: 2022-07-20 Impact factor: 30.153
Authors: Caitlin W Elgarten; Joel C Thompson; Anne Angiolillo; Zhiguo Chen; Susan Conway; Meenakshi Devidas; Sumit Gupta; John A Kairalla; Jennifer L McNeer; Maureen M O'Brien; Karen R Rabin; Rachel E Rau; Susan R Rheingold; Cindy Wang; Charlotte Wood; Elizabeth A Raetz; Mignon L Loh; Sarah Alexander; Tamara P Miller Journal: Pediatr Blood Cancer Date: 2022-09-09 Impact factor: 3.838
Authors: Zachary E West; Sharon M Castellino; Caitlin Monroe; Amanda S Thomas; Courtney McCracken; Tamara P Miller Journal: Leuk Lymphoma Date: 2020-12-01
Authors: Tamara P Miller; Melissa Z Marx; Christopher Henchen; Nicholas P DeGroote; Sally Jones; Jenny Weiland; Beth Fisher; Adam J Esbenshade; Richard Aplenc; Christopher C Dvorak; Brian T Fisher Journal: J Patient Saf Date: 2022-04-01 Impact factor: 2.844